News & Updates

Treatment with vonoprazan, a potassium competitive acid blocker (P-CAB), successfully starts and sustains the healing of Los Angeles (LA) grade C/D esophagitis as compared with proton pump inhibitor (PPI) and has moderate short- and long-term safety, according to a study. On the other hand, other P-CAB therapies need more evidence to prove their advantages.

New drug applications approved by US FDA as of 1-15 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The latest update of the model for end-stage liver disease (MELD), MELD 3.0, predicts mortality in multiethnic Asian patients hospitalized with cirrhosis with greater accuracy than previous models, according to a study from Singapore.

Among adults with moderate-to-severe active ulcerative colitis (UC), treatment with guselkumab, a dual-acting interleukin-23 inhibitor, led to clinical remission at week 44, according to initial data from the phase III QUASAR maintenance study presented at DDW 2024.